[{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thrixopelma pruriens venom peptide","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"OKYO Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"ChemR23","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharma","highestDevelopmentStatusID":"8","companyTruncated":"AmbioPharm \/ AmbioPharma"}]

Find Clinical Drug Pipeline Developments & Deals by AmbioPharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.

                          Brand Name : OK-101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 30, 2022

                          Lead Product(s) : OK-101

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Recipient : OKYO Pharma

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.

                          Brand Name : AMTX-100

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          July 26, 2022

                          Lead Product(s) : AMTX-100

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Amytrx Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.

                          Brand Name : ONL1204

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 12, 2022

                          Lead Product(s) : ONL1204

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : IND Enabling

                          Sponsor : ONL Therapeutics

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.

                          Brand Name : Icatibant Acetate-Generic

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 28, 2021

                          Lead Product(s) : Icatibant Acetate

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved

                          Recipient : Adalvo

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          July 20, 2021

                          Lead Product(s) : Thrixopelma pruriens venom peptide

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : University of California

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.

                          Brand Name : Acthar

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          August 07, 2020

                          Lead Product(s) : Corticotropin

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Upsher-Smith Laboratories

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          July 29, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Undisclosed

                          Recipient : Adalvo

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank